MX9701334A - Metodos para inhibir la degeneracion de protesis oseas. - Google Patents

Metodos para inhibir la degeneracion de protesis oseas.

Info

Publication number
MX9701334A
MX9701334A MX9701334A MX9701334A MX9701334A MX 9701334 A MX9701334 A MX 9701334A MX 9701334 A MX9701334 A MX 9701334A MX 9701334 A MX9701334 A MX 9701334A MX 9701334 A MX9701334 A MX 9701334A
Authority
MX
Mexico
Prior art keywords
inhibiting bone
methods
bone prosthesis
prosthesis degeneration
degeneration
Prior art date
Application number
MX9701334A
Other languages
English (en)
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9701334A publication Critical patent/MX9701334A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion describe un método para inhibir la degeneracion de protesis oseas, que comprende administrar a un humano que lo necesita una cantidad efectiva de un compuesto que tiene la formula (I), en donde R1 y R3 son independientemente hidrogeno, -CH3 (a) o (b), en donde Ar es opcionalmente fenilo substituido; R2 se selecciona del grupo que consiste de pirrolidina, hexametllenimino, y piperidino; o una sal o solvato del mismo farmacéuticamente aceptable.
MX9701334A 1994-08-22 1995-08-21 Metodos para inhibir la degeneracion de protesis oseas. MX9701334A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/294,170 US5550123A (en) 1994-08-22 1994-08-22 Methods for inhibiting bone prosthesis degeneration
PCT/US1995/010616 WO1996005824A1 (en) 1994-08-22 1995-08-21 Methods for inhibiting bone prosthesis degeneration

Publications (1)

Publication Number Publication Date
MX9701334A true MX9701334A (es) 1997-05-31

Family

ID=23132213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701334A MX9701334A (es) 1994-08-22 1995-08-21 Metodos para inhibir la degeneracion de protesis oseas.

Country Status (18)

Country Link
US (1) US5550123A (es)
EP (1) EP0769944A4 (es)
JP (1) JPH10504576A (es)
KR (1) KR970705384A (es)
CN (1) CN1076968C (es)
AU (1) AU701789B2 (es)
CA (1) CA2198118A1 (es)
CZ (1) CZ52097A3 (es)
FI (1) FI970714A0 (es)
HU (1) HUT76825A (es)
IL (1) IL115021A (es)
MX (1) MX9701334A (es)
MY (1) MY132085A (es)
NO (1) NO970786L (es)
NZ (1) NZ292013A (es)
UA (1) UA26204C2 (es)
WO (1) WO1996005824A1 (es)
ZA (1) ZA956990B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US9101978B2 (en) 2002-12-08 2015-08-11 Baker Hughes Incorporated Nanomatrix powder metal compact
US9079246B2 (en) 2009-12-08 2015-07-14 Baker Hughes Incorporated Method of making a nanomatrix powder metal compact
US8403037B2 (en) 2009-12-08 2013-03-26 Baker Hughes Incorporated Dissolvable tool and method
US9227243B2 (en) 2009-12-08 2016-01-05 Baker Hughes Incorporated Method of making a powder metal compact
US8776884B2 (en) 2010-08-09 2014-07-15 Baker Hughes Incorporated Formation treatment system and method
US9139928B2 (en) 2011-06-17 2015-09-22 Baker Hughes Incorporated Corrodible downhole article and method of removing the article from downhole environment
US9057242B2 (en) 2011-08-05 2015-06-16 Baker Hughes Incorporated Method of controlling corrosion rate in downhole article, and downhole article having controlled corrosion rate
US9033055B2 (en) 2011-08-17 2015-05-19 Baker Hughes Incorporated Selectively degradable passage restriction and method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US441868A (en) * 1890-12-02 Mechanical power
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
NO970786D0 (no) 1997-02-20
CN1076968C (zh) 2002-01-02
JPH10504576A (ja) 1998-05-06
NO970786L (no) 1997-02-20
AU3369595A (en) 1996-03-14
WO1996005824A1 (en) 1996-02-29
CA2198118A1 (en) 1996-02-29
NZ292013A (en) 2000-07-28
HUT76825A (en) 1997-11-28
EP0769944A1 (en) 1997-05-02
IL115021A (en) 2000-06-29
UA26204C2 (uk) 1999-07-19
IL115021A0 (en) 1995-12-08
AU701789B2 (en) 1999-02-04
US5550123A (en) 1996-08-27
CN1156406A (zh) 1997-08-06
MY132085A (en) 2007-09-28
CZ52097A3 (en) 1997-08-13
KR970705384A (ko) 1997-10-09
FI970714A (fi) 1997-02-20
FI970714A0 (fi) 1997-02-20
ZA956990B (en) 1997-02-21
EP0769944A4 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".